81 related articles for article (PubMed ID: 25367952)
1. MAFG mediates CIMP in BRAF-mutant colorectal cancer.
Cancer Discov; 2014 Nov; 4(11):OF11. PubMed ID: 25367952
[TBL] [Abstract][Full Text] [Related]
2. The BRAF oncoprotein functions through the transcriptional repressor MAFG to mediate the CpG Island Methylator phenotype.
Fang M; Ou J; Hutchinson L; Green MR
Mol Cell; 2014 Sep; 55(6):904-915. PubMed ID: 25219500
[TBL] [Abstract][Full Text] [Related]
3. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
[TBL] [Abstract][Full Text] [Related]
4. Correlation of laterally spreading type and JC virus with methylator phenotype status in colorectal adenoma.
Nosho K; Yamamoto H; Takahashi T; Mikami M; Hizaki K; Maehata T; Taniguchi H; Yamaoka S; Adachi Y; Itoh F; Imai K; Shinomura Y
Hum Pathol; 2008 May; 39(5):767-75. PubMed ID: 18284934
[TBL] [Abstract][Full Text] [Related]
5. Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis.
Minoo P; Moyer MP; Jass JR
J Pathol; 2007 Jun; 212(2):124-33. PubMed ID: 17427169
[TBL] [Abstract][Full Text] [Related]
6. Common BRAF(V600E)-directed pathway mediates widespread epigenetic silencing in colorectal cancer and melanoma.
Fang M; Hutchinson L; Deng A; Green MR
Proc Natl Acad Sci U S A; 2016 Feb; 113(5):1250-5. PubMed ID: 26787892
[TBL] [Abstract][Full Text] [Related]
7. Unmasking the role of KRAS and BRAF pathways in MSI colorectal tumors.
Seruca R; Velho S; Oliveira C; Leite M; Matos P; Jordan P
Expert Rev Gastroenterol Hepatol; 2009 Feb; 3(1):5-9. PubMed ID: 19210107
[No Abstract] [Full Text] [Related]
8. APC gene methylation is inversely correlated with features of the CpG island methylator phenotype in colorectal cancer.
Iacopetta B; Grieu F; Li W; Ruszkiewicz A; Caruso M; Moore J; Watanabe G; Kawakami K
Int J Cancer; 2006 Nov; 119(10):2272-8. PubMed ID: 16981189
[TBL] [Abstract][Full Text] [Related]
9. The BRAF mutation in MLH1-deficient colorectal cancer.
Mahesh SA
Clin Adv Hematol Oncol; 2013 Apr; 11(4):234-6. PubMed ID: 23604240
[No Abstract] [Full Text] [Related]
10. Annexin A10 expression correlates with serrated pathway features in colorectal carcinoma with microsatellite instability.
Kim JH; Rhee YY; Kim KJ; Cho NY; Lee HS; Kang GH
APMIS; 2014 Dec; 122(12):1187-95. PubMed ID: 24909058
[TBL] [Abstract][Full Text] [Related]
11. BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma.
Affolter K; Samowitz W; Tripp S; Bronner MP
Genes Chromosomes Cancer; 2013 Aug; 52(8):748-52. PubMed ID: 23650027
[TBL] [Abstract][Full Text] [Related]
12. BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status.
Li WQ; Kawakami K; Ruszkiewicz A; Bennett G; Moore J; Iacopetta B
Mol Cancer; 2006 Jan; 5():2. PubMed ID: 16403224
[TBL] [Abstract][Full Text] [Related]
13. Associations of dietary methyl donor intake with MLH1 promoter hypermethylation and related molecular phenotypes in sporadic colorectal cancer.
de Vogel S; Bongaerts BW; Wouters KA; Kester AD; Schouten LJ; de Goeij AF; de Bruïne AP; Goldbohm RA; van den Brandt PA; van Engeland M; Weijenberg MP
Carcinogenesis; 2008 Sep; 29(9):1765-73. PubMed ID: 18339680
[TBL] [Abstract][Full Text] [Related]
14. Distinct CpG island methylation profiles and BRAF mutation status in serrated and adenomatous colorectal polyps.
Kim YH; Kakar S; Cun L; Deng G; Kim YS
Int J Cancer; 2008 Dec; 123(11):2587-93. PubMed ID: 18798261
[TBL] [Abstract][Full Text] [Related]
15. BRAF mutation is associated with the CpG island methylator phenotype in colorectal cancer from young patients.
Ang PW; Li WQ; Soong R; Iacopetta B
Cancer Lett; 2009 Jan; 273(2):221-4. PubMed ID: 18778891
[TBL] [Abstract][Full Text] [Related]
16. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
[TBL] [Abstract][Full Text] [Related]
17. Aberrant methylation of hMLH1 and p16INK4a in Tunisian patients with sporadic colorectal adenocarcinoma.
Miladi-Abdennadher I; Abdelmaksoud-Damak R; Ayadi L; Khabir A; Frikha F; Kallel L; Frikha M; Sellami-Boudawara T; Gargouri A; Mokdad-Gargouri R
Biosci Rep; 2011 Aug; 31(4):257-64. PubMed ID: 20815811
[TBL] [Abstract][Full Text] [Related]
18. p53 mutation is common in microsatellite stable, BRAF mutant colorectal cancers.
Bond CE; Umapathy A; Ramsnes I; Greco SA; Zhen Zhao Z; Mallitt KA; Buttenshaw RL; Montgomery GW; Leggett BA; Whitehall VL
Int J Cancer; 2012 Apr; 130(7):1567-76. PubMed ID: 21557216
[TBL] [Abstract][Full Text] [Related]
19. Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR.
Bettstetter M; Dechant S; Ruemmele P; Grabowski M; Keller G; Holinski-Feder E; Hartmann A; Hofstaedter F; Dietmaier W
Clin Cancer Res; 2007 Jun; 13(11):3221-8. PubMed ID: 17545526
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer.
Ogino S; Kawasaki T; Kirkner GJ; Ogawa A; Dorfman I; Loda M; Fuchs CS
J Pathol; 2006 Oct; 210(2):147-54. PubMed ID: 16850502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
